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nition as a clinical entity of its own is still a matter of debate.
Objective: The aim of this study was to investigate the prevalence of MH and its relation to car-
diovascular risk factors as well as its relation to target organ damage.
Material and methods: A total of 100 patients who were indicated for 24 h ambulatory blood pres-
sure monitoring (ABPM) were enrolled in the study. Blood pressure (BP) was measured in the
clinic, during the following week, echocardiography and ABPM were done. Patients were classiﬁed
into four groups according to clinical BP and ABPM readings: true normotension, sustained hyper-
tension (SH), white coat hypertension (WCH) and MH.
Results: The incidence of MH was 37%. DM was signiﬁcantly higher in SH than MH, also, it was
signiﬁcantly higher in MH than true normotensive patients. Obesity was signiﬁcantly higher in SH
than MH. ABPM readings were signiﬁcantly higher in SH than MH, whereas they were signiﬁcantly
higher in MH than WCH and true normotensive patients. LVH was higher in MH than SH, how-
ever, the difference was not statistically signiﬁcant. LVH was signiﬁcantly higher in MH than WCH
and true normotensive patients.
Conclusion: MH is a common phenomenon and associated with subclinical target organ damage in
the heart comparable to SH and signiﬁcantly higher than WCH and true normotension.
ª 2015 The Author. Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Cardiology.
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nd/4.0/).1. Introduction
Hypertension is increasing in prevalence in Saudi Arabia
affecting more than one fourth of the adult Saudi population.1
The use of ambulatory blood pressure monitoring (ABPM)has added a new source of information about out of ofﬁce
blood pressure (BP). Discrepancies between ofﬁce and out of
ofﬁce BP have resulted in four potential groups of BP status:
ﬁrst, normotensive by both methods (true normotensives); sec-
ond, hypertensive by both (true, or sustained, hypertensives);
third, hypertensive by clinical measurement and normotensive
by ambulatory measurement (white coat hypertensives); and
fourth, normotensive by clinical measurement and hyperten-
sive by ambulatory measurement.2 Masked hypertension
(MH) (or isolated ambulatory hypertension) was ﬁrst
54 A.M. Algamalintroduced by Devereux and Pickering as ‘‘white-coat nor-
motension’’ in 1990.3 According to international guidelines,
elevated daytime ambulatory BP (systolic at least 135 and dias-
tolic at least 85 mmHg) in the face of normal ofﬁce BP (systolic
less than 140 and diastolic less than 90 mmHg) is deﬁned as
masked hypertension.4 The prevalence of MH lies between
8% and 20% among untreated adults, and up to 61% among
treated adults5, MH remains undiagnosed and untreated for a
long period of time.6
All patients who have high normal ofﬁce BP (130–139/
85–89 mmHg) should undergoABPMto rule outMH. If patients
are found to have MH (>135/85 mmHg), the ABPM should be
repeated within 2 months, to conﬁrm the diagnosis (similar to
the recommendation for diagnosis of hypertension). Once MH
is conﬁrmed, patients should undergo comprehensive CV risk
assessment (including ECG, fasting lipid proﬁle, fasting glucose,
basicmetabolic proﬁle, andurinalysis), and they should be treated
with antihypertensive medications, similar to patients with s
ustained hypertension.7About 37%of baselinemaskedhyperten-
sives progressed to sustained hypertension (SH) over time.2
Hypertension is associated with increased CV morbidity
and mortality, guidelines of the European Society of
Hypertension and the European Society of Cardiology to rec-
ommend assessment of asymptomatic organ damage in the
diagnostic workup of hypertensive patients, LVH is highly
prevalent among hypertensive patients.7 The association of
LVH and increased CV morbidity and mortality has been pre-
viously widely documented.8
Studies have reported that associations between MH and
CV diseases are as strong as those found for sustained hyper-
tension.9 Yet, MH recognition as a clinical entity of its own is
still a matter of debate.2
The aim of this study is to investigate the prevalence of MH
and its relation to CV risk factors as well as its relation to
LVMI representing the subclinical target organ damage in
the heart.
2. Patients and methods
This is a prospective, observational study conducted in Olaya
Medical Center (Riyadh) during the period from March 2013
to April 2015. The study protocol was approved by the center’s
ethics committee. A total of 100 patients presented to the car-
diology clinic who were indicated for 24 h ambulatory BP
monitoring were enrolled in the study. These patients pre-
sented with different clinical situations as follows:
– Fluctuating levels of BP in previously non hypertensive
patient.
– To assess control of BP in hypertensive patient.
– Epistaxis associated with high BP in non hypertensive
patient.
– Symptoms suggestive of hypertension as recurrent occipital
headache, dizziness and light headedness with normal
repeated BP readings.
– Patients with high normal BP readings (systolic between
130 and 139 mmhg and diastolic between 85 and 89 mmhg)
– Patients with symptoms suggestive of hypotension.
The arterial BP was measured in the clinic. Brieﬂy, the
patient was allowed to rest for at least 5 min. Then BP wasmeasured by the author three times using a mercuric manome-
ter. The ﬁrst value was rejected and the result was calculated as
the mean of the second and the third value. The procedure was
repeated again after twenty minutes and the result given at the
end was the mean value of the second and the third
measurement.
During the following week, ABPM was initiated in a 24 h
basis by using the apparatus a Oscar 2, SunTech Medical,
Inc., USA. Assessment of the results was done by the author.
The diagnosis of hypertension was made on the basis of
BP = 140 mmHg systolic and/or = 90 mmHg diastolic or
use of antihypertensive medications. Hypertension by 24-h
ambulatory BP was deﬁned when the mean daytime SBP was
equal to or greater than 135 mmHg or when the mean daytime
DBP was equal to or greater than 85 mmHg according to the
report of seventh report of the 2003 US Hypertension Joint
National Committee (JNC 7), European Society of
Hypertension (ESH) and European Society of Cardiology
(ESC) guidelines for hypertension.2 Dipping status was deﬁned
as a percentage drop in the mean BP from wake to sleep peri-
ods. Abnormal dipping was deﬁned as a decline of <10%.10
Patients were classiﬁed into four groups according to clini-
cal BP and ABPM readings: First, the true normotension
group was deﬁned as subjects who were normotensive accord-
ing to both methods; second, the SH group was deﬁned as sub-
jects who were hypertensive by both methods; third, the MH
group was deﬁned as subjects who were normotensive by clin-
ical BP but hypertensive by ambulatory BP; and fourth, the
white coat hypertension group was deﬁned as subjects who
were hypertensive by clinical or ofﬁce BP but normotensive
by ambulatory BP.
It was reported that ambulatory BP is more valuable for
predicting prognosis than other measures, as it more accu-
rately assesses the risk of CV disease than the measurements
of BP made during clinical or ofﬁce visits, and is closely related
to damage to target organs.11 ABPM enables the continuous
observance of changes in BP during activities of daily life, so
that BP can be measured automatically at speciﬁc time inter-
vals (every 30 min or every hour), resulting in very accurate
measurements of BP.12
2.1. Echocardiography
Relative wall thickness (RWT) and left ventricular mass index
(LVMI) were determined by M-mode echocardiography
(ESAOTE Megas CVX machine) automatically using the soft-
ware of the device after entering the patient height and weight.
All echocardiographic examinations were performed and read
by the author.
2.2. Statistical analysis
Data entry and analysis were done using SPSS software.
Continuous and categorical variables are presented as mean
plus or minus standard deviation and percentages, respec-
tively. Mean values between two groups were compared using
independent t test (2-tailed). The means between three or more
groups were compared using analysis of variance (ANOVA).
Chi square test and Fisher Exact test, where appropriate, were
utilized in comparing proportions. A P value <0.05 was con-
sidered statistically signiﬁcant.
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A total of 100 patients indicated for 24 h ambulatory BP mon-
itoring for different reasons were enrolled in the study. They
were 68 males and 32 females with mean age of
49.24 ± 14.99 years. The study included 41 known hyperten-
sive patients, after ABPM, 16 patients of them had MH
(39%) and 25 had SH (61%). In patients with MH (37), 16
patients were hypertensive (43.2%). In patients with SH (31),
25 patients were hypertensive (80.6%). Twenty-seven newly
diagnosed hypertension were detected, 6 of them had SH
(22.2%) and 21 had MH (77.8%).
There were non signiﬁcant difference between groups
regarding age, smoking and BMI (Table 1).
Comparing MH and SH showed non signiﬁcant difference
regarding age, sex and smoking (Table 1). Diabetes mellitus
(DM) and BMI were signiﬁcantly higher in SH than MH
(Table 1). There was signiﬁcantly higher BP readings in
patients with SH than patients with MH regarding clinical
and ABPM readings, however, there was no difference regard-
ing RWT, LVMI and LVH (Table 2).
Comparing MH and WCH showed non signiﬁcant differ-
ence regarding age, DM, smoking and BMI (Table 1). Male
sex incidence was signiﬁcantly higher in MH than WCH
(Table 1). There were signiﬁcantly higher BP readings in
patients with MH than patients with WCH regarding clinical
and ABPM readings except for diastolic ABPM reading in
24 h (Table 2). Also RWT, LVMI and LVH were signiﬁcantly
higher in patients with MH than WCH (Table 2).
Comparing MH and true normotensive patients showed
non signiﬁcant difference regarding sex, DM, smoking, BMI
(Table 1). There were signiﬁcantly higher age (Table 1),
ABPM readings, RWT, LVMI and LVH (Table 2) in patients
with MH than true normotensive patients.
4. Discussion
In the present study, we tried to investigate the prevalence of
masked hypertension and its association with subclinical target
organ damage in the heart represented by LVH as deﬁned by
LVMI >125 g/m2 in males and >110 g/m2 in females. Also,
we compared clinical data, BP readings and LVH in patients
with MH, SH, WCH and true normotensive patients.
Patients were divided according to the results of clinical and
ABPM into 4 groups. The incidence of MH was 37% which is
relatively high, whereas WCH was 7%, SH was 31% and trueTable 1 Clinical data of all patients.
TN (25) SH (31) WCH (7)
Age 42.6 ± 14.82 51.9 ± 14.36 47 ± 19.02
Sex Male 20 (80%) 20 (64.5%) 7 (100%)
Female 5 (20%) 11 (35.5%) 0
DM 7 (28%) 18(58.1%) 1(14.3%)
Smoking 14 (56%) 13 (41.9%) 5(71.4%)
BMI 30.88 ± 4.38 32.42 ± 2.94 31.81 ± 6.41
P1 = difference between all groups, P2 = difference between MH and S
ference between MH and WCH, TN= true normotension, WCH= wh
hypertension, DM= diabetes mellitus, BMI = body mass index.normotension was 25%. These data are in accordance with
Kim et al.,12, Ga et al.,13, the working group for the study of
MH in Spain14 and Selenta et al.15 In our study, the incidence
of WCH was relatively low (7%), this is in accordance with
Kim et al.,12, and contradictory to Ali et al.,16 and Manning
et al.17
The explanation of the high incidence of MH and low inci-
dence of WCH in our study population is not clear. This may
be caused by reduced white coat effect after the patient is
rested and multiple blood pressure readings taken. Also, this
may be explained by factors which selectively augment ambu-
latory BP. These include male gender, alcohol consumption,
obesity, smoking, physical activity, and psychosocial factors
such as anxiety, interpersonal conﬂicts and job stress.18
There was no signiﬁcant difference in age between patients
with MH and patients with SH or WCH, however, age was sig-
niﬁcantly higher in MH than true normotensive patients.
There was no signiﬁcant difference in sex incidence between
patients with MH and patients with SH or true normotensive
patients, however, male sex was signiﬁcantly higher in MH
than WCH. These ﬁndings are in agreement with Kawabe
and Saito,19 Mallion et al.,20 and Trudel et al.21
There was no difference in smoking between groups, this is
in contrast to Kawabe and Saito.19
DM was signiﬁcantly higher in SH than MH, also, it was
signiﬁcantly higher in MH than true normotensive patients,
however, there was no difference between MH and WCH.
This is in accordance with Takeno et al.,22 and contradictory
to Eguchi et al.23
Obesity deﬁned by BMI was signiﬁcantly higher in SH than
MH, there was no difference between MH and WCH or true
normotensive patients, this is discordant with Kotsis et al.,24
and Kim et al.12
There was no signiﬁcant difference between MH and SH
regarding nocturnal dipping, however, it was signiﬁcantly less
in MH than WCH and true normotensive patients. As dimin-
ished nocturnal decline in BP is a risk factor for CV mortality,
independent of the overall BP load during a 24 h period, in the
general population,15 so MH carries more risk than WCH and
true normotension and similar risk as SH.
LVH was higher in MH than SH, however, the difference
was not statistically signiﬁcant. LVH was signiﬁcantly higher
in MH than WCH and true normotensive patients. These data
indicate that patients with MH show subclinical target organ
damage in the heart represented by LVH similar to that found
in SH and signiﬁcantly higher in WCH and true normotensive
patients. These data are in accordance with Tomiyama et al.,25MH (37) P1 value P2 value P3 value P4 value
51.92 ± 13.94 0.063 0.997 0.016 0.417
21 (56.8%) 0.064 0.515 0.058 0.029
16 (43.2%)
11 (29.7%) 0.027 0.019 0.883 0.4
23 (62.2%) 0.298 0.096 0.628 0.64
30.48 ± 4.02 0.233 0.05 0.702 0.425
H, P3 = difference between MH and true normotension, P4 = dif-
ite coat hypertension, MH=masked hypertension, SH = sustained
Table 2 BP readings and echocardiographic ﬁndings of all patients.
TN (25) SH (31) WCH (7) MH (37) P1 value P2 value P3 value P4 value
Clinical BP s 125 ± 6.92 166.29 ± 18.75 155 ± 7.64 125.41 ± 7.49 >0.0001 >0.0001 0.897 >0.0001
Clinical BP d 77.8 ± 5.79 98.55 ± 6.61 93.57 ± 4.76 76.62 ± 6.13 >0.0001 >0.0001 0.459 >0.0001
ABPM s day 130.12 ± 4.04 166.03 ± 9.26 130.86 ± 5.76 153.22 ± 8.48 >0.0001 >0.0001 >0.0001 >0.0001
ABPM d day 80.08 ± 3.23 97.9 ± 4.29 81.86 ± 2.48 93.97 ± 4.29 >0.0001 >0.0001 >0.0001 >0.0001
ABPM s night 118.52 ± 4.09 160.1 ± 10.25 120.29 ± 1.89 146.73 ± 6.84 >0.0001 >0.0001 >0.0001 >0.0001
ABPM d night 70.36 ± 2.2 94.06 ± 5.35 72 ± 1.53 89.43 ± 3.66 >0.0001 >0.0001 >0.0001 >0.0001
ABPM s 24 h 128.84 ± 2.91 165.39 ± 9.16 131.57 ± 1.9 153 ± 8.3 >0.0001 >0.0001 >0.0001 >0.0001
ABPM d 24 h 77.72 ± 4.1 97.16 ± 4.51 88.71 ± 18.22 93.59 ± 4.25 >0.0001 0.02 >0.0001 0.058
Dipping 25 (100%) 7 (22.6%) 6 (85.7%) 15 (40.5%) >0.0001 0.115 >0.0001 0.028
RWT 0.46 ± 0.04 0.59 ± 0.06 0.48 ± 0.05 0.58 ± 0.07 >0.0001 0.468 >0.0001 >0.0001
LVMI 99.92 ± 18.45 174.48 ± 44.82 122 ± 31.23 175.24 ± 51.13 >0.0001 0.941 >0.0001 0.003
LVH 5 (20%) 28 (90.3%) 3 (42.9%) 33 (89.2%) >0.0001 0.878 >0.0001 0.004
P1 = difference between all groups, P2 = difference between MH and SH, P3 = difference between MH and true normotension, P4 = dif-
ference between MH and WCH, TN= true normotension, WCH= white coat hypertension, MH=masked hypertension, SH= sustained
hypertension, BP = blood pressure, s = systolic, d = diastolic, ABPM= ambulatory blood pressure monitoring, RWT= relative wall
thickness, LVMI = left ventricular mass index.
56 A.M. AlgamalPAMELA population,22 Kotsis et al.,24 Hanninen et al.,26 and
Kawano et al.,27 and contradictory to Bombelli et al.28 and
Ormezzano et al.29
5. Conclusion
MH is a common phenomenon and associated with subclinical
target organ damage in the heart comparable to MH and sig-
niﬁcantly higher than WCH and true normotension, so not
every normotensive is truly normotensive and we should screen
for target organ damage in MH patients especially in high risk
patients such as diabetic patients.
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